Breaking News

Vaccines campaign argument in the United States

The future serum to fight against covid-19 is more than ever an important issue for the presidential election across the Atlantic, while the NGO Oxfam accuses rich countries in a report of having reserved more than half of the doses to come to the detriment of the rest of the world.

The future serum to fight against covid-19 is more than ever an important issue for the presidential election across the Atlantic, while the NGO Oxfam accuses rich countries in a report of having reserved more than half of the doses to come to the detriment of the rest of the world.

(AFP) – US President Donald Trump assured Wednesday that the world’s largest economy would have a vaccine in October, which will be widely distributed to the population. Statements that go against the opinions expressed by health experts.

Asked Congress, the director of the Centers for Disease Prevention and Control (CDC), Robert Redfield estimated earlier today that the majority of Americans could not benefit from a vaccine until “the second or third trimester of 2021 ”, even if it was authorized in the coming weeks. An “error” according to Mr. Trump who sees it as “incorrect information”.

“The first responsibility of a president is to protect the American people and he does not do it”, asserted his side the democratic candidate Joe Biden during a speech Wednesday in his stronghold of Wilmington, in Delaware. Donald Trump’s management of the virus “totally disqualifies him”, he said.

13% of the population, 50% of vaccines

In the wake of the United States, which signed several contracts with laboratories to guarantee the delivery of the first available doses, several rich countries, including the United Kingdom, the European Union and Japan, followed the same way, according to a report by the NGO Oxfam. These countries, representing 13% of the world’s population, have pre-purchased half of future doses of covid-19 vaccines, the organization calculates.

The logic of these countries is to source as a precaution from multiple competing manufacturers, in the hope that at least one of their vaccines will prove effective. But the report urgently underlines the difficulty that part of the world population will have in finding vaccines in the initial period, while an international pooling device called Covax, supported by the World Health Organization (WHO), is boycotted by Washington and lacks funding.

According to Oxfam, contracts have already been signed with five of these manufacturers in phase 3 clinical trials for 5.3 billion doses, of which 51% for developed countries. The rest has been pledged to developing countries including India (home to giant manufacturer Serum Institute of India), Bangladesh, China, Brazil, Indonesia and Mexico, according to Oxfam.

A “vaccine nationalism” denounced by multiple public health officials, and by the President of the European Commission Ursula von der Leyen in a speech Wednesday morning before the European Parliament.


Tags

Related Articles

Back to top button
Close
Close